image credit: Adobe Stock

Ori Biotech reaps $100M in series B round to help launch innovative cell manufacturing tech

January 18, 2022

Ori Biotech, which is on the cusp of launching an innovative process for manufacturing cell and gene therapies (CGTs), tallied more than $100 million in its latest funding round.

The company will use the money to add key personnel in all areas of its organization as it gears up for the launch of its CGT manufacturing platform, Ori said.

Additionally, Ori unveiled the launch of its Lightspeed Early Access Program, which provides early access to the manufacturing platform. The tech is scheduled to debut this year, with full commercialization expected in 2023.

Read More on FiercePharma